Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.
The kinetics of the in vitro cytotoxicity of DAB486IL-2, a genetically engineered fusion protein containing a portion of diphtheria toxin and human interleukin-2, were examined in the C91/PL cell line, which constitutively expresses IL-2 receptors. Maximal inhibition of protein synthesis was observed by 4-6 h after DAB486IL-2 addition at a concentration of 300 ng/ml. The tissue distribution, urinary excretion, and plasma pharmacokinetics of DAB486IL-2 in the rat and its plasma pharmacokinetics in the monkey were also examined. In rats the primary site of distribution of [35S]-DAB486IL-2 outside the vasculature appears to be the liver, followed by the kidney, spleen, and lung. Persistence of radioactive material in the liver and urinary excretion of metabolic degradation products suggest that labeled protein is metabolized by hepatic tissue. Following i.v. bolus administration of DAB486IL-2, the initial serum half-life for both the rat and the monkey was approximately 5 min. The overall clearance rate of drug for the two species differed, with DAB486IL-2 being cleared from circulation 2-3 times more rapidly in the monkey. Presence of high levels of neutralizing antibodies to diphtheria toxin in the rat significantly influenced the clearance of bioactive DAB486IL-2. However, the question as to whether the presence of in vitro biological activity for the molecule is masked by the presence of antibodies cannot be clearly answered.
Bacha
P
P
Seragen, Inc., Hopkinton, MA 01748.
Forte
S
S
Kassam
N
N
Thomas
J
J
Akiyoshi
D
D
Waters
C
C
Nichols
J
J
Rosenblum
M
M
D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D004167:Diphtheria Toxin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D004168:Diphtheria Toxoid / Q000276:immunology; D005260:Female; D006801:Humans; D007114:Immunization; D000922:Immunotoxins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D008252:Macaca fascicularis; D008297:Male; D009500:Neutralization Tests; D051381:Rats; D011919:Rats, Inbred Strains; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity; D013462:Sulfur Radioisotopes; D013997:Time Factors; D014018:Tissue Distribution
D000907:Antibodies, Bacterial; C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D004168:Diphtheria Toxoid; D000922:Immunotoxins; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D013462:Sulfur Radioisotopes